Bipolar Disorder Therapeutics
1. Abilify patent expiration
Treatment: Treatment of irritability associated with autistic disorder; Treatment of schizophrenia including maintaining stability in patients with schizophrenia; Treatment of schizophrenia; Treatment of major d...
ABILIFY's oppositions filed in EPO
ABILIFY IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9359302 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(3 years ago) | |
| US8642760 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(3 years ago) | |
| US8580796 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(3 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8642600 | OTSUKA | Method of treating autism |
Jan, 2022
(3 years ago) | |
| US5006528 | OTSUKA | Carbostyril derivatives |
Oct, 2014
(11 years ago) | |
| US9089567 | OTSUKA | Method of treating cognitive impairments and schizophrenias |
Jan, 2022
(3 years ago) | |
| US7053092 | OTSUKA | 5-HT1a receptor subtype agonist |
Jan, 2022
(3 years ago) | |
| US9387182 | OTSUKA | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
Dec, 2023
(2 years ago) | |
|
US8642600 (Pediatric) | OTSUKA | Method of treating autism |
Jul, 2022
(3 years ago) | |
| US8759350 | OTSUKA | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
Mar, 2027
(1 year, 1 month from now) | |
| US8518421 | OTSUKA | Flashmelt oral dosage formulation |
Jan, 2021
(4 years ago) | |
| US6977257 | OTSUKA | Aripiprazole oral solution |
Apr, 2022
(3 years ago) | |
| US9125939 | OTSUKA | Carbostyril derivatives and mood stabilizers for treating mood disorders |
Jul, 2026
(6 months from now) | |
|
US5006528 (Pediatric) | OTSUKA | Carbostyril derivatives |
Apr, 2015
(10 years ago) | |
|
US8518421 (Pediatric) | OTSUKA | Flashmelt oral dosage formulation |
Jul, 2021
(4 years ago) | |
| US9358207 | OTSUKA | Flashmelt oral dosage formulation |
Apr, 2020
(5 years ago) | |
|
US8642760 (Pediatric) | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Mar, 2023
(2 years ago) | |
|
US8580796 (Pediatric) | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Mar, 2023
(2 years ago) | |
|
US6977257 (Pediatric) | OTSUKA | Aripiprazole oral solution |
Oct, 2022
(3 years ago) | |
| US8017615 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Jun, 2024
(1 year, 6 months ago) | |
|
US8017615 (Pediatric) | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Dec, 2024
(1 year, 24 days ago) | |
| US7115587 | OTSUKA | Aripiprazole complex formulation and method |
Jul, 2024
(1 year, 5 months ago) | |
| US7550445 | OTSUKA | Aripiprazole complex formulation and method |
Jul, 2024
(1 year, 5 months ago) | |
|
US7115587 (Pediatric) | OTSUKA | Aripiprazole complex formulation and method |
Jan, 2025
(11 months ago) | |
|
US7550445 (Pediatric) | OTSUKA | Aripiprazole complex formulation and method |
Jan, 2025
(11 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Aug 27, 2011 |
| New Indication(I-616) | Nov 19, 2012 |
| New Indication(I-633) | Feb 16, 2014 |
| M(M-137) | Jun 09, 2017 |
| New Indication(I-700) | Dec 12, 2017 |
| Orphan Drug Exclusivity(ODE) | Dec 12, 2021 |
| Orphan Drug Exclusivity(ODE-80) | Dec 12, 2021 |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 15 November, 2002
Dosage: TABLET; TABLET, ORALLY DISINTEGRATING; INJECTABLE; SOLUTION
How can I launch a generic of ABILIFY before it's drug patent expiration?
More Information on Dosage
ABILIFY family patents
2. Geodon patent expiration
Treatment: Treatment of bipolar disorder
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6150366 | VIATRIS | Ziprasidone formulations |
May, 2019
(6 years ago) | |
| US5312925 | VIATRIS | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride |
Sep, 2012
(13 years ago) | |
| US6245766 | VIATRIS | Method of treating psychiatric conditions |
Dec, 2018
(7 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-615) | Nov 20, 2012 |
| M(M-232) | Jan 28, 2025 |
Drugs and Companies using ZIPRASIDONE HYDROCHLORIDE ingredient
Market Authorisation Date: 05 February, 2001
Dosage: CAPSULE
How can I launch a generic of GEODON before it's drug patent expiration?
More Information on Dosage
GEODON family patents
3. Geodon patent
expiration
Treatment: NA
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6399777 | VIATRIS | Inclusion complexes of aryl-heterocyclic salts |
Apr, 2017
(8 years ago) | |
| US6232304 | VIATRIS | Inclusion complexes of aryl-heterocyclic salts |
Apr, 2017
(8 years ago) | |
| US6110918 | VIATRIS | Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihy dro-2(1H)-indol-2-one (=ziprasidone), its preparation and its use as dopamine D2 antagonist |
Mar, 2017
(8 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-615) | Nov 20, 2012 |
| M(M-232) | Jan 28, 2025 |
Drugs and Companies using ZIPRASIDONE MESYLATE ingredient
Market Authorisation Date: 21 June, 2002
Dosage: POWDER
More Information on Dosage
GEODON family patents
4. Geodon patent expiration
Treatment: Treatment of bipolar disorder; Treatment of psychosis; Treatment of neuroleptic diseases
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7175855 | PFIZER INC | Ziprasidone suspension |
May, 2020
(5 years ago) | |
| US6245766 | PFIZER INC | Method of treating psychiatric conditions |
Dec, 2018
(7 years ago) | |
| US6150366 | PFIZER INC | Ziprasidone formulations |
May, 2019
(6 years ago) | |
| US5312925 | PFIZER INC | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride |
Sep, 2012
(13 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-615) | Nov 20, 2012 |
| M(M-232) | Jan 28, 2025 |
Drugs and Companies using ZIPRASIDONE HYDROCHLORIDE ingredient
Market Authorisation Date: 29 March, 2006
Dosage: SUSPENSION
How can I launch a generic of GEODON before it's drug patent expiration?
More Information on Dosage
GEODON family patents
5. Latuda patent expiration
Treatment: Treatment of major depressive episodes associated with bipolar i disorder; Treatment of schizophrenia; Treatment of bipolar depression with improvement in attention function in
LATUDA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5532372 | SUNOVION PHARMS INC | Imide derivatives, and their production and use |
Jul, 2018
(7 years ago) | |
| USRE45573 | SUNOVION PHARMS INC | Process for producing imide compound |
Jun, 2025
(6 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5532372 | SUNOVION PHARMS INC | Imide derivatives, and their production and use |
Jul, 2018
(7 years ago) | |
| US9815827 | SUNOVION PHARMS INC | Agent for treatment of schizophrenia |
Feb, 2024
(1 year, 10 months ago) | |
|
US5532372 (Pediatric) | SUNOVION PHARMS INC | Imide derivatives, and their production and use |
Jan, 2019
(7 years ago) | |
| US9555027 | SUNOVION PHARMS INC | Pharmaceutical composition |
May, 2026
(4 months from now) | |
| US9827242 | SUNOVION PHARMS INC | Method of treatment for mental disorders |
May, 2031
(5 years from now) | |
| US9174975 | SUNOVION PHARMS INC | Remedy for integration dysfunction syndrome |
Feb, 2024
(1 year, 10 months ago) | |
| US9259423 | SUNOVION PHARMS INC | Method of treatment for mental disorders |
May, 2031
(5 years from now) | |
|
US9174975 (Pediatric) | SUNOVION PHARMS INC | Remedy for integration dysfunction syndrome |
Aug, 2024
(1 year, 4 months ago) | |
| US8729085 | SUNOVION PHARMS INC | Pharmaceutical composition |
May, 2026
(4 months from now) | |
| US9907794 | SUNOVION PHARMS INC | Pharmaceutical composition |
May, 2026
(4 months from now) | |
| US8883794 | SUNOVION PHARMS INC | Pharmaceutical composition |
May, 2026
(4 months from now) | |
|
US8883794 (Pediatric) | SUNOVION PHARMS INC | Pharmaceutical composition |
Nov, 2026
(10 months from now) | |
|
US8729085 (Pediatric) | SUNOVION PHARMS INC | Pharmaceutical composition |
Nov, 2026
(10 months from now) | |
|
US9907794 (Pediatric) | SUNOVION PHARMS INC | Pharmaceutical composition |
Nov, 2026
(10 months from now) | |
|
US9259423 (Pediatric) | SUNOVION PHARMS INC | Method of treatment for mental disorders |
Nov, 2031
(5 years from now) | |
|
USRE45573 (Pediatric) | SUNOVION PHARMS INC | Process for producing imide compound |
Dec, 2025
(17 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-134) | Apr 26, 2015 |
| New Chemical Entity Exclusivity(NCE) | Oct 28, 2015 |
| New Indication(I-674) | Jun 28, 2016 |
| M(M-195) | Jan 27, 2020 |
| Pediatric Exclusivity(PED) | Jul 27, 2020 |
| New Patient Population(NPP) | Mar 05, 2021 |
Drugs and Companies using LURASIDONE HYDROCHLORIDE ingredient
NCE-1 date: 28 July, 2019
Market Authorisation Date: 07 December, 2011
Dosage: TABLET
How can I launch a generic of LATUDA before it's drug patent expiration?
More Information on Dosage
LATUDA family patents
6. Saphris patent expiration
Treatment: Method of treating schizophrenia and bipolar disorder; Use of the atypical antipsychotic asenapine for treatment of manic or mixed episodes ...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7741358 | ALLERGAN | Crystal form of asenapine maleate |
Apr, 2026
(2 months from now) | |
| US8022228 | ALLERGAN | Crystal form of asenapine maleate |
Apr, 2026
(2 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5763476 (Pediatric) | ALLERGAN | Sublingual or buccal pharmaceutical composition |
Dec, 2020
(5 years ago) | |
| US5763476 | ALLERGAN | Sublingual or buccal pharmaceutical composition |
Jun, 2020
(5 years ago) | |
|
US7741358 (Pediatric) | ALLERGAN | Crystal form of asenapine maleate |
Oct, 2026
(8 months from now) | |
|
US8022228 (Pediatric) | ALLERGAN | Crystal form of asenapine maleate |
Oct, 2026
(8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-628) | Sep 03, 2013 |
| New Indication(I-629) | Sep 03, 2013 |
| New Chemical Entity Exclusivity(NCE) | Aug 13, 2014 |
| M(M-158) | Mar 12, 2018 |
| New Patient Population(NPP) | Mar 12, 2018 |
| Pediatric Exclusivity(PED) | Sep 12, 2018 |
| New Dosing Schedule(D-166) | Jan 13, 2020 |
| New Indication(I-597) | Jan 13, 2020 |
Drugs and Companies using ASENAPINE MALEATE ingredient
NCE-1 date: 12 September, 2017
Market Authorisation Date: 12 March, 2015
Dosage: TABLET
How can I launch a generic of SAPHRIS before it's drug patent expiration?
More Information on Dosage
SAPHRIS family patents
7. Vraylar patent expiration
Treatment: Adjunctive therapy to antidepressants for the treatment of major depressive disorder; Treatment of depressive episodes associated with bipolar i disorder (bipolar depression) with cariprazine; Treatme...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7737142 | ABBVIE | (Thio) carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists |
Sep, 2029
(3 years from now) | |
| US7943621 | ABBVIE | Salts of piperazine compounds as D3/D2 antagonists |
Dec, 2028
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE49110 | ABBVIE | Pharmaceutical formulations containing dopamine receptor ligands |
Jul, 2029
(3 years from now) | |
| USRE49302 | ABBVIE | Pharmaceutical formulations containing dopamine receptor ligands |
Jul, 2029
(3 years from now) | |
| USRE47350 | ABBVIE | Pharmaceutical formulations containing dopamine receptor ligands |
Jul, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 17, 2020 |
| M(M-213) | Nov 09, 2020 |
| New Indication(I-798) | May 24, 2022 |
| New Indication(I-904) | Dec 16, 2025 |
Drugs and Companies using CARIPRAZINE HYDROCHLORIDE ingredient
NCE-1 date: 18 September, 2019
Market Authorisation Date: 17 September, 2015
Dosage: CAPSULE
How can I launch a generic of VRAYLAR before it's drug patent expiration?
More Information on Dosage
VRAYLAR family patents